Comparative Pharmacology
Head-to-head clinical analysis: DAPZURA RT versus INVOKAMET XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPZURA RT versus INVOKAMET XR.
DAPZURA RT vs INVOKAMET XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor degrader (SERD) and antagonist; binds to estrogen receptor alpha (ERα), induces its degradation, and inhibits estrogen-dependent growth.
Combination of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which reduces renal glucose reabsorption and lowers blood glucose, and metformin, an activator of AMP-activated protein kinase (AMPK) that decreases hepatic glucose production and improves insulin sensitivity.
20 mg orally once daily
Maximum daily dose: canagliflozin 300 mg/metformin ER 2000 mg orally once daily with the morning meal. Initial dose: canagliflozin 50 mg/metformin ER 500 mg orally twice daily or canagliflozin 150 mg/metformin ER 1000 mg orally once daily; for patients not currently on metformin, start with canagliflozin 50 mg/metformin ER 500 mg orally twice daily; for patients on metformin, switch to INVOKAMET XR based on current metformin dose.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (sufficient for once-daily dosing in most patients; prolonged in renal impairment).
Canagliflozin: mean terminal elimination half-life is 13.1 hours (range 11-16 hours) for the 300 mg dose, consistent with once-daily dosing. Metformin: terminal elimination half-life is approximately 6.2 hours (range 4-9 hours) in patients with normal renal function; prolonged in renal impairment.
Primarily renal: 70-80% unchanged in urine; biliary/fecal excretion accounts for 10-15% as metabolites.
Canagliflozin is primarily excreted as unchanged drug in urine (approximately 33%) and feces (approximately 41%), with about 7% as metabolites in urine and 34% as metabolites in feces. Metformin is excreted unchanged in urine (90-100% of absorbed dose) via tubular secretion and glomerular filtration.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor / Biguanide Combination